Evidence map›Paper›PMID 40076867›Full record

ArticleInternational journal of molecular sciences2025

MELK as a Mediator of Stemness and Metastasis in Aggressive Subtypes of Breast Cancer.

Breanna McBean, Reine Abou Zeidane, Samuel Lichtman-Mikol, Benjamin Hauk, Johnathan Speers, Savannah Tidmore, Citlally Lopez Flores, Priyanka S Rana, Courtney Pisano, Meilan Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Breanna McBeanDepartment of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-3822-2085
Reine Abou ZeidaneDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.ORCID 0009-0004-5009-3150
Samuel Lichtman-MikolDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Benjamin HaukDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.ORCID 0000-0003-0775-6807
Johnathan SpeersDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Savannah TidmoreDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Citlally Lopez FloresDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Priyanka S RanaDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.ORCID 0000-0001-5774-4383
Courtney PisanoDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Meilan LiuDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Alyssa SantolaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Alberto MonteroDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Alan P BoyleDepartment of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-2081-1105
Corey W SpeersDepartment of Radiation Oncology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.ORCID 0000-0002-2362-2860

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
University of Michigan Training Program in Genomic ScienceT32HG000040 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sebastian Zoellner · 1995 to 2026
$16.4M
ASTRO-BCRF Career Development Award to End Cancer N/ANCI NIH HHS P30 CA043703NCI NIH HHS P30 CA046592NHGRI NIH HHS T32 HG000040NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32-HG000040U-M Rogel Cancer Center P30CA046592
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the breast cancer subtype with the poorest prognosis and lacks actionable molecular targets for treatment. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC and has been implicated in poor clinical outcomes, though its mechanistic role in the aggressive biology of TNBC is poorly understood. Here, we demonstrate a role of MELK in TNBC progression and metastasis. Analysis of publicly available datasets revealed that high

Indexed as

Neoplastic Stem CellsProtein Serine-Threonine KinasesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplasm InvasivenessNeoplasm MetastasisPrognosisMELK protein, humanProtein Serine-Threonine KinasesinvasionMELKmetastasismigrationtriple-negative breast cancer (TNBC)tumor initiation

Identifiers

PMID40076867
PMCPMC11900306

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.